Royalty Pharma plc (RPRX)
Nasdaq · Healthcare · Biotechnology
$56.66−0.87%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $32.7B
- P/E (trailing)
- 30.1
- Forward P/E
- 9.9
- Dividend yield
- 1.7%
- 52-week range
- $35.23 – $64.38
- 52-week change
- +58.34%
- EPS (trailing)
- $1.88
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $2.4B (+5.06%)
- Net income
- $771M
- Operating margin
- 65.6%
- Diluted EPS
- $1.78
From the company’s annual report on SEC EDGAR.
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Headquarters: New York, United States · 100 employees · royaltypharma.com